Hirudoid (Mucopolysaccharide Polysulfuric Acid Ester)

Hirudoid is applied to the skin to address several superficial vascular and inflammatory problems, typically in the extremities. Clinical experience in the EU supports its use for the following conditions:

• Bruising (ecchymosis) resulting from minor trauma or surgical procedures.
• Superficial thrombophlebitis affecting small veins of the legs or arms.
• Post‑traumatic swelling and edema of the extremities.
• Mild inflammatory skin conditions such as localized erythema or dermatitis.
• Supportive care after minor injuries to improve microcirculatory flow.
• Reduction of localized hematoma after venipuncture or blood draw.

• Mucopolysaccharide polysulfuric acid ester acts as a topical heparinoid. When applied to the skin it penetrates the superficial dermis and binds to endothelial surfaces, enhancing the activity of tissue plasminogen activator and promoting fibrinolysis. The compound also interferes with platelet‑factor 4, reducing platelet aggregation, and modulates inflammatory mediators such as prostaglandins, leading to improved microcirculatory flow and decreased local edema.

Skin application of Hirudoid may be associated with local or systemic adverse reactions, although most events are mild and reversible.

Common

• Mild skin irritation or a brief burning sensation at the site of application, usually resolving within minutes.
• Transient erythema or localized redness that disappears without treatment.
• Slight itching or pruritus that may be relieved by gentle cleansing.
• Dryness, flaking, or mild peeling of the treated area, often improving with moisturization.

Serious

• Allergic contact dermatitis presenting with redness, swelling, and vesiculation that may require topical corticosteroids.
• Extensive urticaria or angio‑edema involving areas beyond the application site, indicating a systemic response.
• Severe necrosis or ulceration of the skin at the treated location, necessitating medical evaluation.
• Rare systemic hypersensitivity reactions such as anaphylaxis, characterized by respiratory distress, hypotension, and requires emergency care.

When using Hirudoid, certain precautions should be observed to minimize risk and ensure appropriate therapy.

• Avoid application on broken, infected, or ulcerated skin.
• Do not use on mucous membranes, eyes, or genital areas.
• Limit treatment duration to the period recommended by a healthcare professional, typically not exceeding two weeks without reassessment.
• Discontinue use if signs of allergic reaction such as rash, swelling, or severe itching develop.
• Pregnant or breastfeeding individuals should consult a physician before initiating therapy.
• Children and elderly patients may be more susceptible to local irritation and should be monitored closely.

Topical Hirudoid may interact with other agents applied to the skin or systemic medications that affect coagulation.

Avoid

• Concurrent use with other topical heparinoids or strong anticoagulant creams, which could increase the risk of local bleeding.
• Application over areas treated with potent vasodilators or irritant chemicals, as combined effects may exacerbate skin reactions.

Use with caution

• Systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) – monitor for signs of excessive bruising when large skin areas are treated.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) applied topically – may add to anti‑inflammatory effect but increase irritation potential.
• Herbal or homeopathic preparations with blood‑thinning properties (e.g., ginkgo, garlic) – consider reduced frequency of Hirudoid application.